$0.68
+0.06 (+9.68%)
Open$0.62
Previous Close$0.62
Day High$0.78
Day Low$0.61
52W High$2.38
52W Low$0.50
Volume—
Avg Volume716.0K
Market Cap26.37M
P/E Ratio—
EPS$-1.32
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+5,829.4% upside
Current
$0.68
$0.68
Target
$40.32
$40.32
$26.90
$40.32 avg
$53.74
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.73M | 5.14M | 4.74M |
| Net Income | -102,176,432 | 951.6K | 665.5K |
| Profit Margin | -3,740.9% | 18.5% | 14.0% |
| EBITDA | -102,471,540 | 1.31M | 1.24M |
| Free Cash Flow | — | 380.5K | 530.0K |
| Rev Growth | — | -9.9% | +8.5% |
| Debt/Equity | 0.36 | 0.11 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |